This is a email I received from the Company today about the results of
their phase II trials.    Ron,
We expect to present data from the phase IIb trial of NM283 in
treatment refractory patients at AASLD this November.
Best regards,
Amy
                  Looks like they are holding info close to the vest.

                                                             Ron